GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Shares Buyback Ratio %

Sunesis Pharmaceuticals (FRA:RYIS) Shares Buyback Ratio % : -62.56 (As of May. 11, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Sunesis Pharmaceuticals's current shares buyback ratio was -62.56%.


Sunesis Pharmaceuticals Shares Buyback Ratio % Historical Data

The historical data trend for Sunesis Pharmaceuticals's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Shares Buyback Ratio % Chart

Sunesis Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -45.11 -63.88 -9.28 -197.25 -62.56

Sunesis Pharmaceuticals Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 - -0.06 -62.32 -0.08

Sunesis Pharmaceuticals Shares Buyback Ratio % Calculation

Sunesis Pharmaceuticals's Shares Buyback Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2019 ) - Shares Outstanding (EOP) (A: Dec. 2020 )) / Shares Outstanding (EOP) (A: Dec. 2019 )
=(11.1393 - 18.1083) / 11.1393
=-62.56%

Sunesis Pharmaceuticals's Shares Buyback Ratio for the quarter that ended in Dec. 2020 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Sep. 2020 ) - Shares Outstanding (EOP) (A: Dec. 2020 )) / Shares Outstanding (EOP) (A: Sep. 2020 )
=(18.093 - 18.1083) / 18.093
=-0.08%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunesis Pharmaceuticals Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Traded in Other Exchanges
N/A
Address
395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines